FDA’s Accelerated Approval pathway, which gets patients quicker access to new drugs, will not be affected by the Medicaid waiver approved in Oregon yesterday—a win for BIO, biotech innovation, and the people of Oregon.
A few good ideas: When it sought a 1115 waiver to alter the way Medicaid is administered in the state, the Oregon Health Authority added provisions to the state’s Medicaid policy designed to address healthcare inequity and ensure broader coverage, especially for low-income Oregonians.
One bad idea: Oregon’s original waiver application would have limited Medicaid coverage for drugs made available through FDA’s Accelerated Approval pathway, instead allowing the state to conduct its “own rigorous review process to determine coverage of new drugs and to prioritize patient access to clinically proven, effective drugs.”
Fortunately, the provision limiting coverage for Accelerated Approval drugs has been removed, with Oregon’s 2022-2027 1115 waiver approved without it yesterday.
Accelerated Approval is essential: The pathway allows market entry for medications that address critical illnesses with no therapies, based on clinical trials that indicate effectiveness with “surrogate endpoints”—as long as later clinical trials confirm effectiveness. Accelerated Approval has facilitated hundreds of drugs for HIV/AIDS, cancer, and rare diseases, permitting lifesaving treatments, and saving money and lives, a recent report details.
BIO pushed hard to preserve Accelerated Approval in Oregon, through state-level and virtual advocacy and urging the U.S. Centers for Medicare & Medicaid Services (CMS) to preserve Accelerated Approval in the state.
The next steps: Oregon is spared—but future state and federal action may target Accelerated Approval. BIO will continue to work to protect it.
More Health Care News:
CNN: Unvaccinated individuals 14 times more likely to get monkeypox than vaccinated, new US data shows
“These new data provide us with a level of optimism that the vaccine is working as intended,” said CDC Director Dr. Rochelle Walensky of the CDC’s new data.
Science: Big COVID-19 waves may be coming, new Omicron strains suggest
“Several new and highly immune-evasive strains of the virus have caught scientists’ attention in recent weeks; one or more may well cause big, new COVID-19 waves this fall and winter.”